Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo

(2017) Yanjing Song et al.   Protein & Cell

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

(2016) Jae H. Park et al.   BLOOD

Driving gene-engineered T cell immunotherapy of cancer

(2016) Laura A Johnson et al.   CELL RESEARCH

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

(2016) M. V. Maus et al.   CLINICAL CANCER RESEARCH

Prospects for gene-engineered T cell immunotherapy for solid cancers

(2016) Christopher A Klebanoff et al.   NATURE MEDICINE

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

(2016) Gregory L. Beatty et al.   PHARMACOLOGY & THERAPEUTICS

Molecular genetics and targeted therapeutics in biliary tract carcinoma

(2016) Eric I Marks   WORLD JOURNAL OF GASTROENTEROLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

HER2 expression status in diverse cancers: review of results from 37,992 patients

(2015) Min Yan et al.   CANCER AND METASTASIS REVIEWS

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

(2015) X. Liu et al.   CANCER RESEARCH

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

(2015) Hinrich Abken   Immunotherapy

Biliary Tract Cancers: Understudied and Poorly Understood

(2015) Emily Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

(2015) Hanren Dai et al.   OncoImmunology

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

(2014) Yao Wang et al.   CLINICAL IMMUNOLOGY

The biliary tree—a reservoir of multipotent stem cells

(2012) Vincenzo Cardinale et al.   Nature Reviews Gastroenterology & Hepatology

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor

(2011) Yozo Nakazawa et al.   MOLECULAR THERAPY

HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors

(2010) N. Ahmed et al.   CLINICAL CANCER RESEARCH

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy

(2010) Zichen Zhang et al.   HEPATOLOGY

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH